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N2 disease,1,2 mediastinoscopy remains the most popu-
lar diagnostic modality. Some investigators reported that
mediastinoscopy should be performed in all patients
with surgically resectable lung cancer,3-5 whereas oth-
ers concluded that it should be performed only if medi-
astinal lymph nodes are swollen on chest computed
tomography (CT).6-8 This controversy results from the
low sensitivity and specificity of chest CT scan in the
diagnosis of N2 disease.9,10 In an attempt to determine
the indications for mediastinoscopy in lung cancer
cases in which CT scan shows no mediastinal nodal
enlargement, we retrospectively studied patients with
surgically resected lung cancer and identified high-
risk populations who had CT-negative but patho-
logically positive nodal involvement in the medi-
astinum.
P reresectional diagnosis of mediastinal nodal in-volvement (N2) in patients with lung cancer is chal-
lenging. Although the positron emission tomographic
scan has been reported to contribute to the diagnosis of
Objectives: Although preoperative cervical mediastinoscopy is absolutely
indicated for patients with lung cancer in whom computed tomography
demonstrates mediastinal nodal enlargement, the indications when the
computed tomographic scan is negative are controversial. To determine
the indications in patients with negative computed tomographic scans,
we retrospectively studied patients with surgically resected lung cancer.
Methods: Between 1992 and 1997, 379 patients with lung cancer who had
clinical N0-1 disease underwent surgical resection of lung cancer.
Mediastinal lymph nodes were pathologically examined for metastasis in
all the patients. A clinical diagnosis of nodal involvement was deter-
mined on the basis of preoperative computed tomographic findings: that
is, mediastinal or hilar lymph nodes 1.0 cm or larger in the shortest axis
were diagnosed as metastatic. Univariate and multivariate analyses were
performed to determine the relationships between 9 clinical factors and
pathologically proven N2 disease. Results: Among the patients with clin-
ical N0-1 disease, 68 (17.9%) had pathologic N2 disease. Adeno-
carcinoma histology, large tumor dimension, and high serum carci-
noembryonic antigen levels were significant predictors of pathologic N2
disease on the basis of multivariate analyses (P < .05). When these fac-
tors were combined, 43% of adenocarcinomas larger than 2.0 cm with
high serum carcinoembryonic antigen levels (P < .001), 34.7% of adeno-
carcinomas with high serum carcinoembryonic antigen levels (P < .001),
25.6% of adenocarcinomas larger than 2.0 cm (P = .009), and 31.1% of
patients with high serum carcinoembryonic antigen levels and large
tumor dimension (P < .001) had pathologic N2 disease. Conclusion:
Preoperative cervical mediastinoscopy should be considered in patients
in whom computed tomography is negative for lung cancer and who
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CLINICAL PREDICTORS OF N2 DISEASE IN THE SETTING OF A NEGATIVE COMPUTED 
TOMOGRAPHIC SCAN IN PATIENTS WITH LUNG CANCER 
Patients and methods
Between August 1992 and April 1997, 440 patients with
lung cancer underwent surgical resection at our institute.
Mediastinal lymph nodes were pathologically examined for
metastasis in all patients. Among them, 268 were male and
172 were female. Their ages ranged from 22 to 89 years, with
a median of 63 years. All patients underwent thoracic CT
scan before the operation. The CT experiments were carried
out on an X-vision/SP (Toshiba, Tokyo, Japan), and 10-mm
thick contiguous sections were used to evaluate N2 status.
The clinical diagnosis of nodal involvement was determined
by diagnostic radiologists and based on the CT findings: that
is, mediastinal or hilar lymph nodes 1.0 cm or larger in the
shortest axis were diagnosed as metastatic.11
Histologic typing was determined according to the World
Health Organization classification.12 The stage of the disease
was based on the TNM classification of the International
Union Against Cancer.13 Multiple lung carcinomas and hilar
in situ squamous cell carcinomas were excluded from the
study. Patients undergoing less than lobectomy were also
excluded from the study. Only patients undergoing complete
mediastinal lymph node dissection were included. The medi-
astinal lymph node dissection was performed according to the
methods described by Naruke and associates.14 All resected
lymph nodes were formalin fixed and examined microscopi-
cally by standard hematoxylin and eosin stain. The number of
dissected lymph nodes ranged from 4 to 86, with an average
of 29. The number of staff surgeons is four, and they general-
ly perform mediastinal lymph node dissection in the same
manner as described by Naruke. Nodal status during surgical
resection was reported by each staff surgeon.
The median follow-up period for 352 patients who were
alive was 27 months. The length of survival was defined as the
interval in months between the day of surgical resection of
lung carcinoma and the date of death due to any cause or last
follow-up. The survivals were calculated by the Kaplan-Meier
method,15 and univariate analyses were performed by means
of the log rank test. Because the median potential follow-up
time was less than 3 years, we calculated 2-year survivals.
The medical record of each patient was examined for age,
gender, histologic tumor type (adenocarcinoma vs others),
pack-years of smoking, maximum tumor dimension, side of
tumor (left vs right), location of tumor (central vs peripheral),
lobar distribution (upper/middle lobe vs lower lobe), clinical
N status, serum carcinoembryonic antigen (CEA) level (‡ 5.0
vs <5.0 ng/mL) and serum squamous cell carcinoma antigen
(SCC) (‡ 1.5 vs <1.5 ng/mL) levels. Tumor located in the
inner one third of the lung was described as central and the
others as peripheral tumor. Univariate and multivariate
analyses were performed by the logistic regression proce-
dure16 on Statistica 4.1J (Apple Computer, Inc.) with a Power
Macintosh 8100/100AV to determine the relationship
between several clinical factors and pathologic N2 status. In
multivariate analyses, forward and backward stepwise proce-
dures were used to determine the combination of factors that
were essential in predicting pathologic N2 disease. The c 2
test was used to compare the probability of pathologic N2
disease between subgroups in patients with surgically resect-
ed lung cancer.
Results
The nature of the N2 disease is shown in Tables I and
II. As shown in Table II, N2 disease could be stratified
on the basis of either clinical or surgical N status. In
short, the prognosis of clinical or surgical N2 disease
was significantly poorer than that of clinical or surgical
N0-1 disease, respectively.
Of the 440 patients, 102 (23.2%) had pathologic N2
disease (Table III). There were 65 (34.6%) patients
with pathologic N2 disease among 188 patients with an
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Table I. N2 disease according to regional nodal 
stations (n = 102)
Regional nodal stations No. %
Superior mediastinal nodes (n = 66)
No. 1. Highest mediastinal 13  13
No. 2. Paratracheal 6  6
No. 3. Pretracheal 40  39
No. 4. Tracheobronchial angle 49  48
Aortic nodes (n = 28)
No. 5. Subaortic (aortopulmonary window) 19  19
No. 6. Para-aortic (ascending aorta) 19  19
Inferior mediastinal nodes (n = 32)
No. 7. Subcarinal 29  28
No. 8. Paraesophageal 4   4
No. 9. Pulmonary ligament 1   1
Table II. Characteristics of pathologic N2 disease
Survival 
N2 disease No. (%)* P value†
Total N2 disease 102 55.2
Number of metastatic stations
Single station 51 59.9 .69
Multiple stations 51 50.7
Number of metastatic nodes
Single node 18 68.4 .26
Multiple nodes 84 52.3
Mode of metastasis
Non-skip metastasis 66 51.4 .52
Skip metastasis 36 63.2
Clinical N status
Clinical N0-1 68 63.0 .013
Clinical N2 34 37.4
Surgical N status
Surgical N0-1 41 68.3 .026
Surgical N2 61 45.3
*Survival denotes 2-year survival, because the median follow-up time for
patients alive was only 27 months.
†P value in the log-rank test.
elevated serum CEA level (‡ 5.0 ng/mL), whereas 37
(14.6%) patients among 252 with normal serum CEA
level (P < .001) had pathologic N2 disease (pN2).
Tumor size was one of the significant predictors of N2
disease in univariate fashion (P = .003). Clinical N2
status was also a significant predictor of pathologic N2
disease (P < .001): 34 patients (56%) had pathologic
N2 disease among 61 patients with clinical N2 disease.
In multivariate analyses, clinical N2 status and high
serum CEA level were significant predictors of patho-
logic N2 disease (P < .001; Table IV).
Among 379 patients with no mediastinal nodal
swelling on CT scan (clinical N0-1 disease), there were
68 (17.9%) patients with pathologic N2 disease. Nodal
status at the time of surgery is shown in Table V. The
surgeon could not detect lymph node metastases in 35
(51%) of 68 patients with N2 disease. Univariate analy-
ses in the regression model revealed an elevated serum
CEA level (>5.0 ng/mL) and tumor size to be signifi-
cant factors predictive of pathologic N2 disease in this
population (P < .001, P = .047, respectively; Table VI).
In multivariate analyses, tumor size, high serum CEA
level, and adenocarcinoma histology were significant
predictors of pathologic N2 disease (P = .037, .001,
and .014, respectively; Table VII).
When these factors were combined, we found several
subgroups in patients with clinical N0-1 disease that
showed significantly high frequency of pathologically
proven N2 disease (Table VIII). The probability of
pathologic N2 disease in the patients with adenocarcino-
ma larger than 2.0 cm and an elevated serum CEA level
was 43%, and this high frequency was statistically sig-
nificant compared with levels in the remaining patients
with clinical N0-1 disease (P < .001). Similarly, 46% of
the patients with adenocarcinoma larger than 3.0 cm and
a high serum CEA level (P < .001), 35% of patients with
adenocarcinoma and high serum CEA level (P < .001),
25.6% of patients with adenocarcinoma larger than 2.0
cm (P = .009), 30% of those with adenocarcinoma larg-
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Table III. Relationship between clinical features and
presence of pathologic N2 disease among all patients
with surgically resected lung cancer*
No. of Pathologic 
patients N2 Probability†
Total 440 102 (23.2) —
Age (y)‡
Range 22-84 — .70
Median 63 —
Gender
Male 268 61 (25.6) .80
Female 172 41 (23.8)
Pack-years smoking‡
Range 0-148 — .017
Median 25 —
CEA (ng/mL)
<5.0 252 37 (14.6) <.001
5.0≤ 188 65 (34.6)
Serum squamous cell 
carcinoma antigen 
(ng/mL)
<1.5 317 70 (22.1) .68
1.5≤ 74 18 (24)
Side of tumor
Left 178 44 (24.7) .537
Right 262 58 (22.1)
Location of tumor
Central 34 9 (26.4) .64
Peripheral 406 93 (22.9)
Lobar distribution
Upper or middle lobe 293 73 (24.9) .618
Lower lobe 147 29 (19.7)
Tumor size (cm)‡
Range 0.5-10 — .003
Mean 3.46 —
Histology
Squamous 93 20 (21.5) .67
Adenocarcinoma 303 73 (24.1) .501
Others 44 9 (20)
Clinical N status
N0-1 379 68 (17.9) <.001
N2 61 34 (56)
*Numbers in parentheses are percentages. 
†Probability in univariate analyses in logistic regression model.
‡Entered as a continuous variable into the logistic regression model.
Table IV. Multivariate analyses of factors that predict
carrying N2 disease among all patients with surgical-
ly resected lung cancer 
Variables Odds ratio 95% CI P value
Clinical N2
Presence vs absence 4.91 2.74-8.82 <.001
CEA (ng/mL)
‡ 5.0 vs <5.0 2.63 1.63-4.25 <.001
CI, Confidence interval.
Table V. Relationship between surgical N status and
pathologic N status among patients with clinical N0-1
lung cancer (n = 379)
Pathologic N status
Pathologic Pathologic 
Surgical N status N0-1 N2 P value*
Surgical N0-1 298 35 <.0001
Surgical N2 12 33
*P value in the c 2 test.
er than 3.0 cm (P = .019), 31% of those with tumor larg-
er than 2.0 cm with high serum CEA level (P < .001),
and 32% of those with tumor larger than 3.0 cm with
high serum CEA level (P = .003) had pathologic N2 dis-
ease significantly more frequently.
Discussion
We have shown the existence of subgroups of patients
with lung cancer harboring a high probability of patho-
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Table VI. Relationship between clinical features and
presence of pathologic N2 disease in clinical N0-1
cases*
No. of Pathologic 
patients N2 Probability†
Total 379 68 (17.9) —
Age (y)‡
Range 22-84 — .59
Median 63 —
Gender
Male 222 37 (16.7) .525
Female 157 31 (19.7)
Pack-years smoking‡
Range 0-148 — .158
Median 20 —
CEA (ng/mL)
<5.0 230 27 (11.7) <.001
5.0≤ 149 41 (27.5)
Serum squamous cell 
carcinoma antigen 
(ng/mL)
<1.5 280 48 (17.1) .56
1.5≤ 59 12 (20.3)
Side of tumor
Left 150 26 (17.3) .809
Right 229 42 (18.3)
Location of tumor
Central 27 3 (11.1) .33
Peripheral 352 65 (18.5)
Lobar distribution
Upper or middle lobe 250 48 (19.2) .556
Lower lobe 129 20 (15.5)
Tumor size (cm)‡
Range 0.5-10 — .047
Mean 3.27 —
Histology
Squamous 74 9 (12) .15
Adenocarcinoma 270 54 (20.0) .104
Others 35 5 (14)
Clinical N status
N0 342 58 (17.0) .22
N1 37 10 (27)
*Numbers in parentheses are percentages. 
†P value in univariate analyses in logistic regression model. 
‡Entered as a continuous variable into the logistic regression model.
Table VII. Multivariate analyses of factors that pre-
dict pathologic N2 disease in patients with lung can-
cer who have clinical N0-1 disease
Variables Odds ratio 95% CI P value
CEA (ng/mL)
‡ 5.0 vs <5.0 2.87 1.65-4.98 <.001
Histology
Adenocarcinoma 2.37 1.19-4.69 .014
vs others
Tumor size* 1.17 1.01-1.36 .037
*Entered as a continuous variable into the logistic regression model.
Table VIII. The probability of pathologic N2 disease
in subgroups of clinical N0-1 disease with several risk
factors*
Pathologic 
Subgroup No. N2 Probability†
Total clinical N0-1 disease 379 68 (17.9) —
Adenocarcinoma,
high serum CEA level,‡ 
and tumor size > 2 cm
With all of the factors 73 31 (42.5) <.001
With either of the factors 298 37 (12.4)
With neither of the factors 8 0 (0)
Adenocarcinoma,
high serum CEA level,
and tumor size > 3 cm
With all of the factors 46 21 (45.7) <.001
With either of the factors 315 46 (14.6)
With neither of the factors 18 1 (5.6)
Adenocarcinoma 
and high serum CEA level
With both of the factors 98 34 (34.7) <.001
With either of the factors 223 27 (12.1)
With neither of the factors 58 7 (12.1)
Adenocarcinoma 
and > 2 cm in tumor size
With both of the factors 180 46 (25.6) .009
With either of the factors 186 21 (11.3)
With neither of the factors 13 1 (7.7)
Adenocarcinoma 
and > 3 cm in tumor size
With both of the factors 99 29 (29.3) .019
With either of the factors 243 35 (14.4)
With neither of the factors 37 4 (10.8)
High serum CEA level 
and > 2 cm in tumor size
With both of the factors 119 37 (31.1) <.001
With either of the factors 187 26 (13.9)
With neither of the factors 73 5 (6.8)
High serum CEA level 
and > 3 cm in tumor size
With both of the factors 78 25 (32.1) .003
With either of the factors 164 30 (18.3)
With neither of the factors 137 13 (9.5)
*Risk factors were following three factors based on multivariate analysis: ade-
nocarcinoma histology, high serum CEA level, and large tumor size. Numbers
in parentheses are percentages.
† c 2 test. 
‡Serum CEA level ‡ 5 ng/mL.
logic N2 disease in whom CT did not demonstrate
mediastinal nodal enlargement. We think that medi-
astinoscopy should be performed in these high-risk
patients, since they might benefit from preoperative
induction therapy.17 Although some investigators have
reported that all patients with surgically resectable lung
cancer should undergo mediastinoscopy,3-5 our results
indicated that in more than 80% of those with clinical
N0-1 disease the procedure would be unnecessary.
On the other hand, some researchers reported that
mediastinoscopy should be considered in all patients
with CT-demonstrated mediastinal nodal enlargement
(clinical N2), since this factor is a strong predictor of
pathologic N2 disease, to confirm the diagnosis.6-8 Our
results were consistent with these previous reports.
Both univariate and multivariate analyses showed that
clinical N2 disease is a significant predictor of patho-
logic N2 disease. Patients with lung cancer who have
mediastinal lymph node enlargement on chest CT scan
should undergo cervical mediastinoscopy to confirm
the diagnosis. However, false negative CT scanning
rates have been reported to be 18% to 52%.9,10,18,19 The
prognosis of patients undergoing surgical resection for
clinical N0/pathologic N2 lung cancer has been poor,
even though it is better than that of patients with clini-
cal N2/pathological N2 lung cancer.6,20 The former
subgroup of patients might also benefit from preopera-
tive multimodal therapy.17 Therefore preresectional
identification of patients with lung cancer who have
CT-negative microscopic mediastinal involvement is
important.
Mackenzie and Riley21 concluded that mediastin-
oscopy should be omitted in patients who have periph-
eral nodules smaller than 2.0 cm in diameter and a neg-
ative CT examination of the mediastinum. Although
our results were consistent with their report, only
21.4% (59/276) of patients with clinical N0-1 lung can-
cer who had a tumor larger than 2.0 cm had pathologic
N2 disease. This result suggests that about 80% of
patients would undergo unnecessary mediastinoscopy
even in this population. Therefore additional clinical
predictors of pathologic N2 disease are necessary.
In clinical N0-1 cases, there were subgroups with a
high probability of pathologic N2 disease. Multivariate
analyses revealed that an elevated serum CEA level,
adenocarcinoma histology, and tumor size were signif-
icant clinical predictors for pathologic N2 disease. The
following subgroup of patients with clinical N0-1 dis-
ease was considered to include candidates for medi-
astinoscopy because of their significantly high proba-
bility of pathologic N2 disease: adenocarcinoma cases
with a high serum CEA level or a maximum tumor
dimension larger than 2.0 cm, or both. Reed and
Sugarbaker17 reported that mediastinoscopy was rela-
tively indicated for lesions located within the inner one
third of the lung field. However, according to our
results, the centrally located lung carcinoma did not
necessarily associate with the presence of N2 disease.
In contrast, our results also showed that patients with
clinical N0-1 lung cancer have a very low probability
of having N2 disease. For the following population,
preoperative mediastinoscopy would not be indicated;
otherwise, more than 90% of patients would undergo
unnecessary mediastinoscopy (Table VIII): (1) patients
with non-adenocarcinoma 2.0 cm or less in size and
normal serum CEA level and (2) patients with any lung
carcinoma 2.0 cm or less in size and normal serum
CEA level.
In conclusion, we have delineated subgroups of
patients with clinical N0-1 lung cancer who have a high
probability of pathologic N2 disease. Mediastinoscopy
should be considered in these subgroups to preopera-
tively identify patients with minimal mediastinal
lymph node involvement.
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